公开(公告)号：EP1852129A4

公开(公告)日：2009-07-15

申请号：EP06713158

申请日：2006-02-07

申请人： ASTELLAS PHARMA INC

发明人： AKUZAWA SHINOBU ,  ITO HIROYUKI ,  WATANABE TOSHIHIRO ,  YAMADA HIROYOSHI

IPC分类号： A61K45/00 ,  A61K31/166 ,  A61K31/343 ,  A61K31/351 ,  A61K31/352 ,  A61K31/385 ,  A61K31/41 ,  A61K31/4168 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/426 ,  A61K45/06 ,  A61P1/04 ,  C07D233/88 ,  C07D249/14 ,  C07D257/06 ,  C07D263/28 ,  C07D277/18 ,  C07D277/20 ,  C07D277/38 ,  C07D277/46

CPC分类号： A61K31/438 ,  A61K31/085 ,  A61K31/16 ,  A61K31/166 ,  A61K31/215 ,  A61K31/343 ,  A61K31/351 ,  A61K31/352 ,  A61K31/385 ,  A61K31/403 ,  A61K31/41 ,  A61K31/4168 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/426 ,  A61K45/06 ,  C07D209/54 ,  C07D221/20 ,  C07D233/88 ,  C07D249/14 ,  C07D257/06 ,  C07D263/28 ,  C07D277/18 ,  C07D303/06 ,  C07D305/14 ,  C07D307/94 ,  C07D319/14 ,  C07D327/02 ,  C07D333/50 ,  C07D335/04 ,  A61K2300/00

摘要： A remedy for IBS comprising, as the active ingredient, a dual antagonist for 5-HT2B and 5-HT7 receptors which shows selective binding affinities to 5-HT2B and 5-HT7 receptors. The above-described medicinal composition is superior in the pharmacological effect to each of the cases of using an antagonist for 5-HT2B receptor which has a selective binding affinity for 5-HT2B receptor alone and using an antagonist for 5-HT7 receptor which has a selective binding affinity for 5-HT7 receptor alone. Thus, this medicinal composition is useful as a drug which is excellent in the therapeutic effect on IBS and shows lessened side effects occurring in the existing remedies for IBS.